Allergan CEO on $40.5 Billion Teva deal
Allergan CEO Brent Saunders discusses the company’s recent selloff of its generic business to Teva for $40.5 billion.
Allergan CEO Brent Saunders discusses the company’s recent selloff of its generic business to Teva for $40.5 billion.